,31 However, as KEAP1 mutations frequently co-occur with STK11 mutations in clinical samples, which is also known to modulate the tumor immune milieu,23,32,33 these clinical observations suggest that NRF2 may act collaboratively with STK11 to cause the lower-level immune cell infiltrations in the tumors. This evidence concerns the gene NFE2L2 and neoplasm.